Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

  • Marzena WAtek
  • Tomasz Wollny
  • Marcin Pasiarski
  • Stanislaw Gozdz
  • Bonita Durnas
  • Przemyslaw Wolak
  • Robert Bucki
  • Marzec, Michal Tomasz
  • Anna Chabowska
  • Malgorzata Zendzian-Piotrowska
BACKGROUND: Impaired apoptotic pathways in leukemic cells enable them to grow in an uncontrolled way. Moreover, aberrations in the apoptotic pathways are the main factor of leukemic cells drug resistance. METHODS: To assess the presence of potential abnormalities that might promote dysfunction of leukemic cells growth, HPLC system was used to determine sphingosine (SFO), sphinganine (SFA), sphingosine-1-phosphate (S1P) and ceramide (CER) concentration in the blood collected from patients diagnose with acute myeloblastic leukemia (AML; n = 49) and compare to values of control (healthily) group (n = 51). Additionally, in AML group concentration of SFO, SFA, S1P and CER was determined in bone marrow plasma and compared to respective values in blood plasma. The concentration of S1P and CER binding protein - plasma gelsolin (GSN) was also assessed in collected samples using immunoblotting assay. RESULTS: We observed that in AML patients the average SFO, SFA and CER concentration in blood plasma was significantly higher (p <0.001) compare to control group, when blood plasma S1P concentration was significantly lower (p <0.001). At the same time the CER/S1P ratio in AML patient (44.5 ± 19.4) was about 54% higher compare to control group (20.9 ± 13.1). Interestingly the average concentration of S1P in blood plasma (196 ± 13 pmol/ml) was higher compare to its concentration in plasma collected from bone marrow (154 ± 21 pmol/ml). CONCLUSIONS: We hypothesize that changes in profile of sphingolipids concentration and some of their binding protein partners such as GSN in extracellular environment of blood and bone marrow cells in leukemic patients can be targeted to develop new AML treatment method(s).[on SciFinder (R)]
Original languageEnglish
JournalLipids in Health and Disease
Issue number1
Publication statusPublished - 2017
Externally publishedYes

Bibliographical note

M1 - Copyright (C) 2018 U.S. National Library of Medicine.

MEDLINE AN 2019291140(Journal; Article; (JOURNAL ARTICLE))

    Research areas

  • acute myeloid leukemia, ceramide, hematological malignancies, plasma gelsolin, s1p, sphingolipids

ID: 202376691